Clinical trial
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed…
NCT00323115 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00323115 |
|---|---|
| Title | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme |
| Official title | A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Biological, Drug, Procedure |
| Interventions | Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine |
| Enrollment | 11 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Jul 1, 2013 |
| First posted | May 9, 2006 |
| Last update posted | Oct 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: